Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

1. Baselga, J.
2. Im, S.-A.
3. Iwata, H.
4. Cortés, J.
5. De Laurentiis, M.
6. Jiang, Z.
7. Arteaga, C.L.
8. Jonat, W.
9. Clemons, M.
10. Ito, Y.
11. Awada, A.
12. Chia, S.
13. Jagiełło-Gruszfeld, A.
14. Pistilli, B.
15. Tseng, L.-M.
16. Hurvitz, S.
17. Masuda, N.
18. Takahashi, M.
19. Vuylsteke, P.
20. Hachemi, S.
21. Dharan, B.
22. Di Tomaso, E.
23. Urban, P.
24. Massacesi, C.
25. Campone, M.